BioSig Technologies, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. (BSGM) on May 4, 2021. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market. The report primarily addresses a Regulation FD disclosure regarding updated operational targets for the company's Pure EP System.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational guidance rather than financial statement data.
Material Changes and Operational Updates
The Company announced an increase in its procedural volume targets for the Pure EP System. The target has been raised from 1,000 procedures to at least 1,500 procedures by the end of 2021.
Guidance, Outlook, and Risks
Management has provided updated forward-looking guidance regarding procedural volumes. The filing explicitly states that the Company undertakes no obligation to update, supplement, or amend the materials attached. The information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific details of the press release attached as Exhibit 99.1 for full context on the Pure EP System.
- Confirm the current status of procedural volumes against the new target of 1,500 procedures.
- Review subsequent filings for any updates to financial performance, as this 8-K contains no financial data.
- Note that the Company has disclaimed any obligation to update this specific guidance.